Hanspeter Nick

Medicine · Health Sciences

25h-index2.8kcitations67works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Iron Metabolism and Disorders(32), Hemoglobinopathies and Related Disorders(29), Trace Elements in Health(10), Nerve injury and regeneration(5), Crystallization and Solubility Studies(5)

Publications67 total

193 Prostaglandin-mediated activation of CFTR and calcium-activated chloride channels in primary airway epithelia
Journal of Cystic Fibrosis·2024
Biomechanische Modellierung der Handwurzel
Zeitschrift für Orthopädie und Unfallchirurgie·2014· 8 cited
Identification of Cardiac Glycoside Molecules as Inhibitors of c-Myc IRES-Mediated Translation
SLAS DISCOVERY·2012· 32 citedOpen Access
Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats
Experimental Hematology·2012· 14 cited
Iron Chelation Therapy in Hereditary Hemochromatosis and Thalassemia Intermedia: Regulatory and Non Regulatory Mechanisms of Increased Iron Absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251–264]
Hemoglobin·2011· 5 cited
The Effect of Supplemental Ascorbate on Defersirox Iron Chelation In the Iron-Loaded Gerbil
Blood·2010
Comparison of Two Animal Models for Evaluation of Defersirox Iron Chelation
Blood·2010
Ability of deferasirox to bind iron during measurement of iron
Clinical Chemistry and Laboratory Medicine (CCLM)·2010· 4 cited
Growth Inhibition of Human Breast Cancer Cells with an Iron Chelator (Deferasirox) and Docetaxel.
Cancer Research·2009· 1 cited
Deferasirox Reduces Iron Overload in a Murine Model of Juvenile Hemochromatosis
Experimental Biology and Medicine·2009· 25 cited
Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with <b>β</b>‐thalassaemia
European Journal Of Haematology·2008· 75 citedOpen Access
Effect of Deferasirox (Exjade®) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial
Blood·2008· 19 cited
Pharmacokinetics, Distribution, Metabolism, and Excretion of Deferasirox and Its Iron Complex in Rats
Drug Metabolism and Disposition·2008· 82 cited
Influence of iron chelation on R1 and R2 calibration curves in gerbil liver and heart
Magnetic Resonance in Medicine·2008· 17 citedOpen Access
Safety and Efficacy of Combined Chelation Therapy with Deferasirox and Deferoxamine in a Gerbil Model of Iron Overload
Acta Haematologica·2008· 31 citedOpen Access
Susceptibility of Endocrine, Cardiac, and Macrophage Cell Lines to Iron-Mediated Oxidative Damage and the Cytoprotective Effect of the Orally Active Chelator Deferasirox (Exjade®, ICL670).
Blood·2007
Iron Chelator ICL670 Inhibits HIV-1 Transcription.
Blood·2007
Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism
Cell Proliferation·2007· 41 citedOpen Access
Iron chelation, quo vadis?
Current Opinion in Chemical Biology·2007· 38 cited
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy
Experimental Hematology·2007· 27 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

John C. Wood(10), Maya Otto‐Duessel(10), Michelle Aguilar(8), Denis Monard(7), Rex Moats(7), Marvin D. Nelson(5), Bernard Faller(4), Alì Taher(4), Thomas D. Coates(3), S. Steinhauser(3), Uwe Heinz(3), Mark Bartholomä(3), Thomas Weyhermüller(3), Κ. Hegetschweiler(3), Jan Hofsteenge(3), David Farley(3), Shahina Daar(3), Anil Pathare(3), Joachim Guenther(2), Hava Glickstein(2)